FMP
XOMA Corporation
XOMA
NASDAQ
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
20.19 USD
1.43 (7.08%)
Historical Prices
From:
To:
About
ceo
Mr. Owen P. Hughes Jr.
sector
Healthcare
industry
Biotechnology
website
https://www.xoma.comexchange
NASDAQ
Description
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
CIK
0000791908
ISIN
US98419J2069
CUSIP
98419J206
Address
2200 Powell Street
Phone
510 204 7200
Country
US
Employee
13
IPO Date
Jun 6, 1986
Financial Statement
Earnings
XOMA Financial Summary
CIK
0000791908
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
98419J206
ISIN
US98419J2069
Country
US
Price
20.19
Beta
1
Volume Avg.
39.89k
Market Cap
241.85M
Shares
-
52-Week
18.35-35
DCF
-2.23
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-12.24
P/B
-
Website
https://www.xoma.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest XOMA News
Zacks Investment Research
Aug 13, 2024
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago.
Seeking Alpha
Jul 19, 2024
My 2 Top Royalty Income Picks, Yields Up To 9.5%
My 2 Top Royalty Income Picks, Yields Up To 9.5%
Zacks Investment Research
Jul 18, 2024
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Ga...
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seeking Alpha
Jun 29, 2024
XOMA Corporation: A Hold Rating With Steady Income From Pref...
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various therapeutic areas, including oncology, immunology, rare diseases, and acute pain, mitigating investment risks. The recent acquisition of Kinnate Biopharma extends XOMA's portfolio into oncology despite Kinnate selling its crown jewel, exarafenib, before the acquisition.
Zacks Investment Research
Jun 21, 2024
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock...
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
InvestorPlace
Jun 12, 2024
3 Crazy Good Stocks to Buy With $500 Right Now
Although there was a time when the stock market was solely the playground of the wealthy, it no longer takes money to make money on Wall Street. The democratization of investing means even those with only a few dollars to spare can start building a retirement nest egg — and it won't even cost you anything to buy and sell shares.
GlobeNewsWire
May 14, 2024
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Inv...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.
Zacks Investment Research
May 7, 2024
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahe...
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
